162 related articles for article (PubMed ID: 10894301)
1. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Perloff MD; von Moltke LL; Fahey JM; Daily JP; Greenblatt DJ
AIDS; 2000 Jun; 14(9):1287-9. PubMed ID: 10894301
[No Abstract] [Full Text] [Related]
2. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
3. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
4. [Resistance to protease inhibitors].
Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
[No Abstract] [Full Text] [Related]
5. Resistance to human immunodeficiency virus type 1 protease inhibitors.
Boden D; Markowitz M
Antimicrob Agents Chemother; 1998 Nov; 42(11):2775-83. PubMed ID: 9797203
[No Abstract] [Full Text] [Related]
6. The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
Piliero PJ
AIDS; 2002 Mar; 16(5):799-800. PubMed ID: 11964541
[No Abstract] [Full Text] [Related]
7. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
8. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
9. Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Lucia MB; Anu R; Handley M; Gillet JP; Wu CP; De Donatis GM; Cauda R; Gottesman MM
Br J Cancer; 2011 Aug; 105(4):513-22. PubMed ID: 21829205
[TBL] [Abstract][Full Text] [Related]
10. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
Dupuis ML; Flego M; Molinari A; Cianfriglia M
HIV Med; 2003 Oct; 4(4):338-45. PubMed ID: 14525546
[TBL] [Abstract][Full Text] [Related]
11. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
Zhang L; Gorset W; Washington CB; Blaschke TF; Kroetz DL; Giacomini KM
Drug Metab Dispos; 2000 Mar; 28(3):329-34. PubMed ID: 10681378
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
13. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
14. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Lucia MB; Rutella S; Leone G; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
[TBL] [Abstract][Full Text] [Related]
15. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
16. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Vernochet C; Azoulay S; Duval D; Guedj R; Ailhaud G; Dani C
AIDS; 2003 Oct; 17(15):2177-80. PubMed ID: 14523274
[TBL] [Abstract][Full Text] [Related]
18. Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
Jain RG; Lenhard JM
J Biol Chem; 2002 May; 277(22):19247-50. PubMed ID: 11937496
[TBL] [Abstract][Full Text] [Related]
19. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Lenhard JM; Furfine ES; Jain RG; Ittoop O; Orband-Miller LA; Blanchard SG; Paulik MA; Weiel JE
Antiviral Res; 2000 Aug; 47(2):121-9. PubMed ID: 10996400
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line.
Dupuis ML; Tombesi M; Sabatini M; Cianfriglia M
Chemotherapy; 2003 May; 49(1-2):8-16. PubMed ID: 12714803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]